Experimental HIV vaccine trial ends early – what we know
NCT ID NCT05470400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental HIV vaccine in 44 healthy adults to see if it was safe and triggered an immune response. The vaccine uses a piece of the HIV virus (fusion peptide) to train the body's defenses. The study was terminated early, so the full results are not available, but the goal was to gather safety data for future vaccine development.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HIV-1 fusion peptide conjugate vaccine (FP8v1-rTTHC) with Adjuplex adjuvant, alone or with HIV-1 envelope trimer vaccines
What this could lead to
If successful, this could help develop a vaccine that trains the immune system to recognize and fight HIV.
What could go wrong
This was a very early (phase 1) trial focused only on safety and immune response, not on preventing HIV. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta - Hope Clinic
Atlanta, Georgia, 30308, United States
-
BIDMC Vcrs [32077]
Boston, Massachusetts, 02115, United States
-
Columbia P&S CRS [30329]
New York, New York, 30329, United States
-
New York Blood Center CRS [31801]
New York, New York, 10065, United States
-
University of Pittsburgh CRS [1001]
Pittsburgh, Pennsylvania, 15213, United States
-
University of Rochester Vaccines to Prevent HIV Infection CRS [31467]
Rochester, New York, 14642, United States